Member Info for prospero17

Agree completely. Just another example of Brexit Britain being a horrible place to invest, and the AIM is completely unfit for purpose. I will never invest in any UK Biotechs again. I had invested in RENE since 2007 but got out at 28p a couple of months ago and have felt much happier it isn't wrecking my portfolio anymore. It's just been a long line downwards for 15 years.

And the SP still goes down. I think RENE would have to cure cancer, world hunger and organise world peace for the SP to go up.

Sorry RiseOfThePorper, I've just seen your previous post and you say you are buying in? Why would you buy shares and short at the same time?

Good luck, IMHO I can't see too much more downside from here as the valuation is effectively cash and nothing for any of the IP. Having said that unless there's a surprise announcement I can't see it going upwards much either.

I thought it was a 1:100 consolidation?

Heads need to roll now. SP down over 90% in 15 years.

It will drop back down and will continue to do so until the company actually gets something to market. I've been invested for 14 years and we alway seems years away, deadlines routinely missed and failed products swept under the carpet.

Not sure I agree with your logic about wanting a large spread between offer and bid Clive. It reduces liquidity and stops people buying if they see that they effectively pay e.g 10% more than the price they can sell at. Far better would be to get off the AIM.

I'm more interested to know what all these employees have been doing over the last year and how much money is left.

Thanks for the pep talk Clive, we really need it. I don't dare sell my shareholdings as I've had so much invested in this company and believe in the science. It would be a sickener for it to take off just afterwards.

Actually historically with goods news the price rises beforehand and then drifts down almost immediately. With bad news it tanks, and with no news it gradually drifts lower. Based on 14 years of experience which has seen the SP drop 85% in that time, while the rest of my portfolio is up around 200% over the same period. How can the SP be a seventh of what it was 14 years ago based on the technological, funding and licencing advances?

Hardly surprising with no CFO, delays to trials, a medical issue and no deals or other positive news publicised.

Thanks for posting the full article Cadbury, and good points Phil. Have a good week all.

Thanks Cadbury, any chance you could post the whole article here, as you need to sign up unfortunately.

A lot of buys coming in which is reassuring. Perhaps people realise a 3 month delay on one product line isn't the end of the world.

Looks like more a Sam Allerdyce than a Guardiola or Tuchel. Not someone to take us to another level, that's for sure.

Anyone know anything about this chap?

Appointment of Chief Scientific Officer

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the appointment of Dr Stefano Pluchino as Chief Scientific Officer with immediate effect. Dr Pluchino will join the Company on a part-time basis and brings with him a wealth of knowledge of cell and gene therapy.

Dr Stefano Pluchino is Reader in Regenerative Neuroimmunology and Honorary Consultant at the University of Cambridge since 2010. He obtained his MD and PhD at the University of Siena, Italy, and progressed to two consecutive post doctorate appointments at the San Raffaele Scientific Institute in Milan, Italy.

Dr Pluchino has published over 120 peer-reviewed papers, including several in top journals, including Nature, Cell and Cell Stem Cell, and is internationally recognised as a leader and pioneer in the field of regenerative neuroimmunology. He was the recipient of the 2003 European Charcot Foundation (ECF) Award, the 2006 Serono Foundation Multiple Sclerosis Award, the 2007 Rita Levi-Montalcini award, hosted by the Italian Foundation for Multiple Sclerosis, the 2009 Italian Ministry of Health Young Investigator Award and the 2010 International Royan Award for outstanding research in Stem Cell Biology and Technology.

Olav Hellebø, Chief Executive Officer, commented: "We are delighted to welcome Dr Pluchino to ReNeuron. His extensive experience of cell and gene therapy as well as deep knowledge in the exosomes field will be invaluable to us in what is an incredibly exciting and progressive time. Dr Pluchino's work is widely recognised, and we look forward to working alongside him, as ReNeuron continues to grow and develop its pipeline."

When the market goes up we get left behind. When it goes down 2-3% we go down 10%...

Couldn't agree more Phil, the Woodford debacle caused havoc for many British healthcare SMEs, after a very long frustrating period for RENE investors it was the icing on the cake. At least that is all behind us, and for the first time in years I'm quite optomistic as many key milestones are in the pipeline. GLA.

Just found an Edison report from 2016: 'Our valuation has increased to £249m (vs £233m) or 7.9p per share (vs 7.4p per share)'. Considering the advances made and large licencing deal made, a market cap of a third of that now looks ridiculous.